Inogen, Inc. ( INGN ) NASDAQ Global Select

Cena: 7.75 ( 2.92% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Medical - Devices
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Inogen, Inc., firma zajmująca się technologią medyczną, rozwija, produkuje i sprzedaje przenośne koncentratory tlenu dla pacjentów, lekarzy i innych klinicystów oraz płatników innych firm w Stanach Zjednoczonych i na arenie międzynarodowej. Jego koncentratory tlenu są wykorzystywane do dostarczania dodatkowej długoterminowej terapii tlenu u pacjentów cierpiących na przewlekłe warunki oddechowe. Firma oferuje inogen One, przenośne urządzenie, które koncentruje powietrze wokół pacjenta, aby zapewnić jedno źródło dodatkowego tlenu; Inogen w domu stacjonarnych koncentratorów tlenu; Inogen pływowy wspomagaj wentylatory, a także powiązane akcesoria. Firma wynajmuje również swoje produkty bezpośrednio pacjentom. Inogen, Inc. został włączony w 2001 roku i ma siedzibę w Goleta w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 834
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 97.544
Ilość akcji: Brak danych
Debiut giełdowy: 2014-02-14
WWW: https://www.inogen.com
CEO: Mr. Kevin R. M. Smith
Adres: 301 Coromar Drive
Siedziba: 93117 Goleta
ISIN: US45780L1044
Wskaźniki finansowe
Kapitalizacja (USD) 209 563 100
Aktywa: 306 172 000
Cena: 7.75
Wskaźnik Altman Z-Score: 1.4
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -7.3
Ilość akcji w obrocie: 98%
Średni wolumen: 236 575
Ilość akcji 27 040 400
Wskaźniki finansowe
Przychody TTM 331 520 000
Zobowiązania: 120 768 000
Przedział 52 tyg.: 5.7 - 13.33
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -1.1
P/E branży: 29.9
Beta: 1.045
Raport okresowy: 2025-11-06
WWW: https://www.inogen.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Kevin R. M. Smith President, Chief Executive Officer & Director 1 624 254 1971
Mr. Grgoire Ramade Executive Vice President & Chief Commercial Officer 0 1970
Ms. Jennifer Yi Boyer Executive Vice President & Chief Human Resources Officer 0 0
Mr. Michael J. Bourque Executive Vice President, Chief Financial Officer & Treasurer 0 1963
Mr. Philip Corrin Senior Vice President of Operations & Supply Chain 0 0
Mr. Kevin P. Smith General Counsel & Executive Vice President of Business Development 0 0
Lista ETF z ekspozycją na akcje Inogen, Inc.
Symbol ETF Ilość akcji Wartość
IWM 586 409 3 700 239
IWN 213 843 1 349 352
DFAT 159 547 1 006 741
VTWO 121 108 851 389
DFAS 68 628 433 042
IWC 56 749 358 088
VFMF 52 830 371 394
PRFZ 52 059 340 986
VFMO 50 756 356 814
AVSC 48 419 317 144
R2SC.L 35 741 177 401
ZPRR.DE 35 741 205 004
R2US.L 35 741 234 103
DFAC 25 888 163 353
VFVA 19 897 139 875
VFQY 16 392 115 235
VTWV 15 693 110 321
XRS2.DE 15 349 84 815
XRSU.L 15 349 96 854
XRSG.L 15 349 7 339 563
RSSL 12 681 80 017
QQQS 5 822 38 134
IWV 4 811 30 359
XSU.TO 4 058 36 728
DFAU 3 394 21 416
DXUV 2 852 17 996
AVUS 2 676 17 527
UWM 2 407 15 188
URTY 1 993 12 575
VTHR 1 612 11 332
SCDS 1 118 7 054
AVSU 66 432
HDG 29 182
DCOR 8 50
RTYS.L 0 14 363
PZW.TO 0 1 596
SC0K.DE 0 12 584
Wiadomości dla Inogen, Inc.
Tytuł Treść Źródło Aktualizacja Link
What Makes Inogen (INGN) a New Buy Stock Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-05-16 17:01:10 Czytaj oryginał (ang.)
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN) Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com 2025-05-16 14:35:12 Czytaj oryginał (ang.)
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales. zacks.com 2025-05-08 17:10:57 Czytaj oryginał (ang.)
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Colin Clark - Stifel Mike Matteson - Needham & Company Margaret Andrew - William Blair Operator Welcome to Inogen's First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-05-08 00:16:06 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-05-08 00:05:40 Czytaj oryginał (ang.)
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago. zacks.com 2025-05-07 23:01:04 Czytaj oryginał (ang.)
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins. zacks.com 2025-05-06 15:15:45 Czytaj oryginał (ang.)
Here's Why You Should Retain Inogen Stock in Your Portfolio Now Expanding product portfolio and high prospects for POC raise optimism for INGN stock. zacks.com 2025-04-16 12:10:33 Czytaj oryginał (ang.)
Inogen To Present at 24th Annual Needham Virtual Healthcare Conference GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference. businesswire.com 2025-03-20 10:30:00 Czytaj oryginał (ang.)
Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-03-13 12:30:58 Czytaj oryginał (ang.)
Here's Why You Should Retain Inogen Stock in Your Portfolio Now Inogen, Inc.  INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified. zacks.com 2025-03-11 11:40:27 Czytaj oryginał (ang.)
A Volatile Share Price Masks Some Of The Progress At Inogen Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. seekingalpha.com 2025-03-01 10:56:06 Czytaj oryginał (ang.)
What's Going On With MedTech Focused Inogen Stock On Wednesday? Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents. benzinga.com 2025-02-26 18:21:16 Czytaj oryginał (ang.)
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales. zacks.com 2025-02-26 14:10:27 Czytaj oryginał (ang.)
Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-02-25 22:03:12 Czytaj oryginał (ang.)
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago. zacks.com 2025-02-25 20:56:15 Czytaj oryginał (ang.)
Here's Why You Should Add Inogen Stock to Your Portfolio Now Expanding product portfolio and high prospects for POC raise optimism for INGN stock. zacks.com 2025-02-06 10:31:12 Czytaj oryginał (ang.)
Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West. businesswire.com 2025-02-03 18:00:00 Czytaj oryginał (ang.)
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market. zacks.com 2025-01-28 13:21:29 Czytaj oryginał (ang.)
Arab Health 2025｜Yuwell Medical Announces Strategic Investment and Partnership with Inogen in Respiratory Health DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai , and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration. Speaking at the Yuwell Medical 2025 Global Core Partner Conference, Alex WU, Chairman of Yuwell Medical, stated that as a leading enterprise in China's home medical device industry, Yuwell will rely on internal growth and external mergers and acquisitions to promote internationalisation. prnewswire.com 2025-01-27 00:17:00 Czytaj oryginał (ang.)
Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration With Yuwell GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration with Yuwell. businesswire.com 2025-01-26 14:00:00 Czytaj oryginał (ang.)
Inogen (INGN) Moves to Strong Buy: Rationale Behind the Upgrade Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2025-01-24 15:01:10 Czytaj oryginał (ang.)
Inogen Stock Gains Following Solid Preliminary Q4 Revenues INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products. zacks.com 2025-01-15 15:00:53 Czytaj oryginał (ang.)
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue. businesswire.com 2025-01-13 18:00:00 Czytaj oryginał (ang.)
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device. zacks.com 2024-12-31 12:41:00 Czytaj oryginał (ang.)
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device. businesswire.com 2024-12-30 10:30:00 Czytaj oryginał (ang.)
Here's Why You Should Retain Inogen Stock in Your Portfolio Now Expanding product portfolio and high prospects for POC raise optimism for INGN stock. zacks.com 2024-12-24 16:31:07 Czytaj oryginał (ang.)
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog. zacks.com 2024-12-12 05:16:11 Czytaj oryginał (ang.)
5 Medical Device Stocks That Survived the 2024 Market Volatility Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025. zacks.com 2024-12-11 10:55:37 Czytaj oryginał (ang.)
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com 2024-11-25 12:56:31 Czytaj oryginał (ang.)
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales. zacks.com 2024-11-11 13:31:08 Czytaj oryginał (ang.)
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript Call Start: 17:00 January 1, 0000 5:26 PM ET Inogen, Inc. (NASDAQ:INGN ) Q3 2024 Earnings Conference Call November 7, 2024, 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Mike Matson - Needham Operator Welcome to Inogen's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-11-09 23:55:32 Czytaj oryginał (ang.)
Inogen (INGN) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2024-11-08 23:00:46 Czytaj oryginał (ang.)
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.97 per share a year ago. zacks.com 2024-11-07 21:10:31 Czytaj oryginał (ang.)
Here's Why You Should Retain Inogen Stock in Your Portfolio Now Expanding product portfolio and high prospects for POC raise optimism for INGN stock. zacks.com 2024-10-18 13:50:22 Czytaj oryginał (ang.)
Inogen to Report Third Quarter 2024 Financial Results on November 7, 2024 GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #COPD--Inogen to Report Third Quarter 2024 Financial Results on November 7, 2024. businesswire.com 2024-10-17 12:30:00 Czytaj oryginał (ang.)
Inogen Stock Rises 47% in 6 Months: What's Driving the Rally? INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology. zacks.com 2024-10-04 15:55:25 Czytaj oryginał (ang.)
Here's Why You Should Add Inogen Stock to Your Portfolio Now Expanding product portfolio and high prospects for POC raise optimism for the INGN stock. zacks.com 2024-09-16 12:51:06 Czytaj oryginał (ang.)
Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock? Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock. zacks.com 2024-08-22 18:20:26 Czytaj oryginał (ang.)
Inogen (INGN) Reports Q2 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-08-08 17:01:23 Czytaj oryginał (ang.)
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales. zacks.com 2024-08-07 16:36:03 Czytaj oryginał (ang.)
Inogen, Inc. (INGN) Q2 2024 Earnings Call Transcript Inogen, Inc. (NASDAQ:INGN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Ryan Peterson - IR Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan James Beer - William Blair Colin Clark - Stifel Michael Matson - Needham & Company Operator Welcome to Inogen's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, August 6, 2024. seekingalpha.com 2024-08-07 01:11:09 Czytaj oryginał (ang.)
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates Inogen (INGN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.42 per share a year ago. zacks.com 2024-08-06 23:05:23 Czytaj oryginał (ang.)
3 Stocks Under $10 With the Potential for Massive Gains Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. investorplace.com 2024-07-22 10:24:00 Czytaj oryginał (ang.)